Table 4.
Number of participants reporting adverse events by rs4680 genotype group
| Variable | GG | Non-GG | ||||
|---|---|---|---|---|---|---|
| Adverse event | Group M (n = 29) no. (%) |
Group O (n = 30) no. (%) |
P value | Group M (n = 41) no. (%) |
Group O (n = 39) no. (%) |
P value |
| Somnolence | 12 (41.4) | 11 (36.7) | .79 | 18 (43.9) | 13 (33.3) | .49 |
| Nausea | 8 (27.6) | 8 (26.7) | 1.00 | 12 (29.3) | 10 (25.6) | .81 |
| Vomiting | 5 (17.2) | 6 (20.0) | 1.00 | 8 (19.5) | 5 (12.8) | .55 |
| Constipation | 13 (44.8) | 10 (33.3) | .43 | 20 (48.8) | 19 (48.7) | 1.00 |
| Delirium | 1 (3.4) | 0 (0.0) | .49 | 2 (4.9) | 3 (7.7) | .67 |
| Others | 3 (10.3) | 0 (0.0) | .11 | 1 (2.4) | 0 (0.0) | 1.00 |
Abbreviations: group M, morphine-treated group; group O, oxycodone-treated group.